Joinn Laboratories(China)Co.,Ltd. (603127.SS)
- Previous Close
19.83 - Open
19.66 - Bid 19.52 x --
- Ask 19.53 x --
- Day's Range
19.31 - 19.81 - 52 Week Range
12.32 - 23.48 - Volume
27,378,914 - Avg. Volume
23,429,590 - Market Cap (intraday)
13.979B - Beta (5Y Monthly) 0.69
- PE Ratio (TTM)
38.27 - EPS (TTM)
0.51 - Earnings Date Aug 28, 2025 - Sep 1, 2025
- Forward Dividend & Yield 0.16 (0.81%)
- Ex-Dividend Date Jul 31, 2024
- 1y Target Est
--
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics studies, and pharmacology and efficacy studies. The Clinical Trial and Related Services segment provides clinical CRO services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment designs, produces, breeds, and sells research models, non-human primates, and rodents. The company also offers cell-based assay (CBA) services. Joinn Laboratories(China)Co.,Ltd. was founded in 1995 and is headquartered in Beijing, China.
www.joinn-lab.com2,652
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 603127.SS
View MorePerformance Overview: 603127.SS
Trailing total returns as of 6/11/2025, which may include dividends or other distributions. Benchmark is 000001.SS (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 603127.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 603127.SS
View MoreValuation Measures
Market Cap
14.20B
Enterprise Value
12.08B
Trailing P/E
38.88
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.58
Price/Book (mrq)
1.83
Enterprise Value/Revenue
6.10
Enterprise Value/EBITDA
27.07
Financial Highlights
Profitability and Income Statement
Profit Margin
19.56%
Return on Assets (ttm)
0.46%
Return on Equity (ttm)
4.77%
Revenue (ttm)
1.98B
Net Income Avi to Common (ttm)
387.42M
Diluted EPS (ttm)
0.51
Balance Sheet and Cash Flow
Total Cash (mrq)
2.17B
Total Debt/Equity (mrq)
0.65%
Levered Free Cash Flow (ttm)
296.69M